Heart fatty acid-binding protein offers similar diagnostic performance to high-sensitivity troponin T in emergency room patients presenting with chest pain

Circulation Journal

Volumn 75, Issue 12, 2011, Pages 2813-2820

  Inoue, Kenji ^a   Suwa, Satoru ^e   Ohta, Hiroshi ^c   Itoh, Seigo ^b   Maruyama, Sonomi ^a   Masuda, Nobuhito ^d   Sugita, Manabu ^a   Daida, Hiroyuki ^b  

^a JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Itabashi Chuo General Hospital   (Japan)

^d Perseus Proteomics   (Japan)

^e JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

Author keywords

Acute coronary syndrome; Biomarker; Diagnostic performance

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FATTY ACID BINDING PROTEIN; MYELOPEROXIDASE; PENTRAXIN 3; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; EMERGENCY CARE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SENSITIVITY AND SPECIFICITY; THORAX PAIN;

ACUTE CORONARY SYNDROME; AGED; C-REACTIVE PROTEIN; CHEST PAIN; CROSS-SECTIONAL STUDIES; EMERGENCY MEDICAL SERVICES; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEROXIDASE; SERUM AMYLOID P-COMPONENT; TROPONIN T;

EID: 82455163818     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0598     Document Type: Article

References (24)

1. Chan CP, Wan TS, Watkins KL, Pelsers MM, Van der Voort D, Tang FP, et al. Rapid analysis of fatty acid-binding proteins with immunosensors and immunotests for early monitoring of tissue injury. Biosens Bioelectron 2005; 20: 2566-2580.
2. Alhadi HA, Fox KA. Do we need additional markers of myocyte necrosis: The potential value of heart fatty-acid-binding protein. QJM 2004; 97: 187-198.
3. Hsu BG, Chen YC, Lee RP, Lee CC, Lee CJ, Wang JH. Fasting serum level of fatty-acid-binding protein 4 positively correlates with metabolic syndrome in patients with coronary artery disease. Circ J 2010; 74: 327-331.
4. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286: 2136-2142.
5. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: The EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007; 50: 159-165.
6. Chang LT, Chua S, Sheu JJ, Wu CJ, Yeh KH, Yang CH, et al. Level and prognostic value of serum myeloperoxidase in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J 2009; 73: 726-731.
7. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109: 1955-1959.
8. Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: The Third National Health and Nutrition Examination Survey. Arch Intern Med 2005; 165: 2063-2068.
9. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol 2006; 45: 326-330.
10. Kotooka N, Inoue T, Fujimatsu D, Morooka T, Hashimoto S, Hikichi Y, et al. Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 2008; 197: 368-374.
11. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008; 155: 75-81.
12. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007; 115: e356-e375.
13. Mingels A, Jacobs L, Michielsen E, Swaanenburg J, Wodzig W, van Dieijen-Visser M. Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin Chem 2009; 55: 101-108.
14. Melanson SE, Morrow DA, Jarolim P. Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am J Clin Pathol 2007; 128: 282-286.
15. Bakshi TK, Choo MK, Edwards CC, Scott AG, Hart HH, Armstrong GP. Causes of elevated troponin I with a normal coronary angiogram. Intern Med J 2002; 32: 520-525.
16. Fernandes CJ Jr, Akamine N, Knobel E. Cardiac troponin: A new serum marker of myocardial injury in sepsis. Intensive Care Med 1999; 25: 1165-1168.
17. Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis: Experimental and clinical correlates. Circulation 1997; 95: 163-168.
18. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007; 27: 161-167.
19. Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med 2009; 47: 471-477.
20. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-969.
21. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy: Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998; 31: 1460-1465.
22. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94: 437-444.
23. Mad P, Domanovits H, Fazelnia C, Stiassny K, Russmüller G, Cseh A, et al. Human heart-type fatty-acid-binding protein as a point-ofcare test in the early diagnosis of acute myocardial infarction. QJM 2007; 100: 203-210.
24. Kurz K, Giannitsis E, Becker M, Hess G, Zdunek D, Katus HA. Comparison of the new high sensitive cardiac troponin T with myoglobin, h-FABP and cTnT for early identification of myocardial necrosis in the acute coronary syndrome. Clin Res Cardiol 2011; 100: 209-215.